article thumbnail

2 Large-Cap Stocks That Have Roughly Doubled Nvidia's Returns Over the Past Year

The Motley Fool

Two stocks that have roughly doubled Nvidia's returns over the past 12 months include Super Micro Computer (NASDAQ: SMCI) and Carvana (NYSE: CVNA). Here's a look at their returns over this time frame and why they have been such hot buys, and whether they still make for good investments today. billion it reported in the previous year.

Returns 246
article thumbnail

Taiwan Semiconductor Feels Confident About Its Long-Term Prospects

The Motley Fool

Fool.com contributor Parkev Tatevosian highlights why Taiwan Semiconductor Manufacturing (NYSE: TSM) feels so strongly about its growth prospects. The 10 stocks that made the cut could produce monster returns in the coming years. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*.

Prospects 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Meet the Ultrahigh-Yield Dividend Stock That Helped 1 Member of Congress Generate a 122% Return Last Year

The Motley Fool

That's the goal for most investors. Meet the ultrahigh-yield dividend stock that helped one member of Congress generate a 122% return last year. Meet the ultrahigh-yield dividend stock that helped one member of Congress generate a 122% return last year. He achieved a return of 122%. Beat the market. Mark Green, R-Tenn.,

Returns 246
article thumbnail

SoundHound AI Is Optimistic About Its Long-Term Prospects to 2025 and Beyond

The Motley Fool

Fool.com contributor Parkev Tatevosian elaborates on SoundHound AI 's (NASDAQ: SOUN) longer-term prospects. Before you buy stock in SoundHound AI, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and SoundHound AI wasn’t one of them.

Prospects 130
article thumbnail

Ozempic Won't Sink This Medical Device Stock's Prospects -- Quite the Opposite

The Motley Fool

Some investors thought GLP-1 medicines such as Ozempic could decrease demand for some of Abbott's key products. Abbott's prospects remain strong Abbott Laboratories has an excellent track record of developing innovative medical devices. Here's the bottom line: Abbott Laboratories is still a top pick for long-term investors.

Prospects 130
article thumbnail

Forget Aurora Cannabis: 1 Cannabis Stock With Far Better Prospects

The Motley Fool

But when it comes to having "far better prospects" than Aurora Cannabis, which hasn't yet definitively proven it can turn a profit, I'd say that Green Thumb -- which has proven this -- probably fits that bill. The wild card: Legalization Final point: For investors who aren't yet entirely convinced that the U.S. national level.

Prospects 189
article thumbnail

Fact or Fiction: Congress Stole From Social Security and Should Return the Money It's Taken, With Interest

The Motley Fool

America's leading retirement program is facing the prospect of sweeping benefit cuts in under a decade, and the finger-pointing as to how this illustrious program got into this mess has begun. The bank is going to loan out your money and aim to generate a higher rate of return than what it's paying you in interest.

Returns 246